Daily Anesthesiology Research Analysis
Analyzed 48 papers and selected 3 impactful papers.
Summary
Three studies with immediate relevance to anesthesiology and critical care stood out: two randomized controlled trials addressing prevention of perioperative complications (paroxysmal sympathetic hyperactivity after TBI; hypoxemia during pediatric procedural sedation) and one randomized trial exploring dexmedetomidine’s effects on cerebral homeostasis in craniotomy. Collectively, they emphasize proactive monitoring, targeted prophylaxis, and biologically plausible neuroinflammatory modulation.
Research Themes
- Prophylaxis of perioperative complications in neurocritical care
- Enhanced respiratory monitoring to prevent hypoxemia during pediatric sedation
- Neuroinflammation and biomarker modulation with dexmedetomidine in neurosurgery
Selected Articles
1. Propranolol monotherapy versus combined propranolol-gabapentin for prevention of paroxysmal sympathetic hyperactivity after moderate-severe traumatic brain injury: a randomized controlled trial.
In adults with moderate-to-severe TBI, prophylactic propranolol reduced PSH incidence (33.3% vs 60% vs 10% with propranolol+gabapentin) and shortened mechanical ventilation and ICU length of stay. Adding gabapentin further reduced PSH but was associated with longer ventilator days and ICU stay compared with propranolol alone.
Impact: This pragmatic RCT addresses a common, morbid neurocritical complication lacking prophylactic guidance and provides actionable dosing parameters for beta-blocker prophylaxis.
Clinical Implications: Consider initiating propranolol prophylaxis in moderate-to-severe TBI to reduce PSH and streamline ICU course; reserve gabapentin for refractory cases while monitoring for potential delays in liberation from ventilation and ICU discharge.
Key Findings
- PSH incidence: 10% (propranolol+gabapentin) vs 33.3% (propranolol) vs 60% (control), p<0.001
- Shortest MV duration in propranolol group: 5.92±5.15 days vs 9.42±6.99 (combo), 12.92±5.98 (control)
- ICU LOS shortest in propranolol group: 9.6±5.32 days vs 14.69±8.35 (combo), 19.5±8.19 (control)
- No significant differences in mortality or GCS improvement among groups
Methodological Strengths
- Prospective randomized, three-arm design with pre-registration (NCT05427474)
- Clinically meaningful primary and secondary endpoints relevant to ICU operations
Limitations
- Single-center trial with modest sample size (n=90)
- Blinding and sedation/analgesia protocols not fully detailed, potential confounding
Future Directions: Confirm in multicenter RCTs with standardized sedation protocols, explore dose-response, and assess long-term neurological and functional outcomes.
BACKGROUND: Paroxysmal sympathetic hyperactivity (PSH) is a serious complication of traumatic brain injury (TBI), characterized by episodic hypertension (HTN), tachycardia, hyperthermia, hyperhidrosis, and dystonia. It is associated with prolonged mechanical ventilation (MV), extended ICU and hospital stays, and worse outcomes. Current guidelines lack prophylactic recommendations. METHODOLOGY: This single-center randomized controlled trial (NCT05427474) enrolled 90 adults with moderate-to-severe TBI glasgow coma scale (GCS 3-12). Participants were randomized to: standard care (Group I, n = 30); standard care plus propranolol (40 mg/12 h, Group II, n = 30); or standard care plus propranolol (40 mg/12 h) and gabapentin (100 mg/8 h, Group III, n = 30). The primary endpoint was PSH incidence. Secondary endpoints included ventilator days, ICU and hospital length of stay (LOS), and mortality. RESULTS: PSH incidence was lowest in Group III (10%) vs. Group II (33.3%) and Group I (60%) (p < 0.001). Group II showed the shortest MV duration (5.92 ± 5.15 days) vs. Group III (9.42 ± 6.99 days, p = 0.047) and Group I (12.92 ± 5.98 days, p < 0.001). ICU LOS was shortest in Group II (9.6 ± 5.32 days) vs. Group III (14.69 ± 8.35 days, p = 0.017) and Group I (19.5 ± 8.19 days, p < 0.001). Mortality and GCS improvement did not differ significantly (p > 0.05). CONCLUSION: Prophylactic propranolol significantly reduces PSH incidence, shortens MV duration, and decreases ICU stay in moderate-to-severe TBI. Although adding gabapentin further reduces PSH, it prolongs recovery time, suggesting a trade-off between efficacy and sedative effects. These findings suggest that propranolol monotherapy is a promising prophylactic strategy, with gabapentin potentially reserved for refractory cases. However, given the study's limitations, these results should be considered hypothesis-generating and warrant confirmation in larger, multicenter trials. Mortality and neurological outcomes were comparable across groups. TRIAL REGISTRATION: The trial was prospectively registered at ClinicalTrials.gov (NCT05427474) on June 22, 2022.
2. Effect of dexmedetomidine on cerebral homeostasis in patients undergoing craniotomy for brain tumour excision: A randomized double-blind trial.
Dexmedetomidine as an adjunct reduced propofol requirements, transiently improved cerebral oxygenation indices, and attenuated neuroinjury and inflammatory biomarkers (S100B, NSE, TNF-α, IL-6, cortisol) within 24 hours after craniotomy. These effects suggest biologically plausible neuroinflammatory modulation but do not yet prove clinical neuroprotection.
Impact: Provides mechanistic and physiological evidence supporting dexmedetomidine’s role in neurosurgical anesthesia, informing biomarker-driven perioperative strategies.
Clinical Implications: Dexmedetomidine may be considered to reduce anesthetic requirements and modulate neuroinflammation during craniotomy, with careful hemodynamic monitoring given transient changes.
Key Findings
- Reduced propofol consumption in the dexmedetomidine group (p<0.001)
- Transient improvement (≈15 minutes) in cerebral oxygenation indices during infusion (p<0.05)
- Lower postoperative S100B, NSE, TNF-α, IL-6, and cortisol at 6–24 hours (p<0.01)
Methodological Strengths
- Randomized, double-blind design with predefined sampling time-points
- Comprehensive physiological and biomarker assessment (arterial and jugular-bulb sampling)
Limitations
- Modest sample size (n=56) limits power for clinical endpoints
- Improvements in oxygenation were transient and surrogate outcomes predominate
Future Directions: Larger RCTs powered for neurological outcomes and long-term cognition; dose-response and hemodynamic safety profiling.
AIM: Dexmedetomidine (DEX) seems to hold a potential neuroprotective role, possibly mediated by the attenuation of oxidative stress and neuroinflammation. This study aimed to delineate the effect of DEX used as an adjunct anaesthetic on cerebral oxygenation, cerebral injury and the release of inflammatory markers in brain tumour surgery. METHODS: Fifty-six patients undergoing craniotomy for brain tumour excision were randomly assigned to receive either DEX (1 μg/kg for 10 min and thereafter 0.7 μg/kg/h) or placebo. Arterial and jugular-bulb blood samples were collected at predefined time-points, whereas a concomitant hemodynamic profile was obtained intraoperatively. S100B protein, neuron-specific enolase (NSE), tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6) and cortisol levels were determined at baseline and 6 and 24 h postoperatively. RESULTS: Demographic and perioperative characteristics were comparable between groups. Propofol consumption was considerably reduced in DEX-treated patients (p < 0.001). Measured (jugular-bulb oxygen saturation and partial pressure of oxygen) and estimated (oxygen and carbon dioxide arterial-jugular differences, brain oxygen extraction ratio) cerebral oxygenation indices were favourably affected by DEX infusion (p < 0.05), yet this effect was valid for 15 min (p < 0.05), corresponding to transient systemic hemodynamic augmentation. Moreover, postoperative S100B, NSE, TNF-α, IL-6 and cortisol levels were significantly attenuated in the DEX group (p < 0.01). CONCLUSION: DEX may attenuate the release of cerebral injury and neuroinflammation biomarkers and transiently improve hemodynamics and cerebral oxygenation during brain tumour surgery. Nonetheless, these surrogate effects do not establish clinically relevant neuroprotection, and potential dose-related hemodynamic instability warrants cautious, individualized use.
3. Capnography With Integrated Pulmonary Index for Preventing Hypoxemia During Pediatric Urologic Surgery Under Sedation: A Randomized Controlled Trial.
In pediatric urologic procedures under procedural sedation, adding capnography plus Integrated Pulmonary Index to standard monitoring reduced intraoperative desaturation and severe hypoxemia, and decreased invasive ventilation needs via earlier airway interventions.
Impact: Demonstrates that enhanced respiratory monitoring strategies can meaningfully reduce hypoxemia during pediatric sedation, a common and modifiable perioperative risk.
Clinical Implications: Incorporate capnography and IPI into pediatric sedation monitoring to enable earlier airway maneuvers and reduce severe desaturation and invasive ventilation.
Key Findings
- Desaturation reduced: 34.33% vs 56.06% (OR 0.410; 95% CI 0.203–0.825; P=0.012)
- Severe desaturation (SpO₂<90%) reduced: 19.40% vs 36.40% (OR 0.421; 95% CI 0.192–0.925; P=0.034)
- Earlier airway responses: more jaw thrusts (1.84±1.31 vs 1.17±1.12; P=0.004) and less invasive positive-pressure ventilation (P=0.002)
Methodological Strengths
- Prospective randomized controlled design with registered protocol (ChiCTR 2300073943)
- Clear clinical endpoints and actionable airway management metrics
Limitations
- Single-center study with moderate sample size
- Potential Hawthorne effect due to enhanced monitoring awareness
Future Directions: Validate across diverse procedures and sedation regimens; cost-effectiveness and alarm fatigue evaluation; integration into pediatric sedation guidelines.
BACKGROUND Procedural sedation and analgesia (PSA) can relieve pain and anxiety during invasive procedures. Carbon dioxide (CO₂) monitoring or integrated pulmonary index (IPI) can reduce respiratory depression in adults with PSA, but the effect of the combination of these 2 methods on intraoperative hypoxemia in pediatric urologic surgery is unclear. This study was conducted to determine whether capnography combined with IPI could lessen intraoperative hypoxemia during pediatric urinary procedures with PSA. MATERIAL AND METHODS We conducted a randomized controlled trial (ChiCTR 2300073943). Children referred for urinary procedures with PSA were randomly assigned to either a control group with standard monitoring or an intervention group with standard monitoring combined with capnography and IPI monitoring. The primary outcome was intraoperative hypoxemia. Secondary outcomes were severe intraoperative hypoxemia, airway management, and perioperative complications. RESULTS A total of 133 patients completed the analysis (67 in the intervention group and 66 in the control group). Compared with the control group, the incidence of intraoperative oxygen saturation decline was significantly lower in the intervention group (34.33% vs 56.06%, odds ratio=0.410, 95% confidence interval: 0.203-0.825, P=0.012). Simultaneously, the incidence of severe oxygen desaturation (SpO₂ <90%) was also significantly reduced in the intervention group (19.40% vs 36.40%, odds ratio=0.421, 95% confidence interval: 0.192-0.925, P=0.034). Regarding airway management interventions, the intervention group exhibited a higher frequency of jaw thrust maneuvers (1.84±1.31 vs 1.17±1.12 times, P=0.004) and a significantly reduced need for invasive positive-pressure ventilation (1.64±1.31 vs 2.39±1.48, P=0.002). No differences in other airway management techniques or perioperative complications were observed between the 2 groups. CONCLUSIONS The addition of capnography and IPI monitoring to standard monitoring reduces the risk of intraoperative hypoxemia in pediatric urologic surgery and reduces the need for aggressive ventilation through early intervention.